» Articles » PMID: 17645507

The Influence of Reproductive and Hormonal Factors on Ovarian Cancer Survival

Overview
Date 2007 Jul 25
PMID 17645507
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Reproductive and hormonal exposures are known to influence ovarian carcinogenesis, but little is known about the effect of these factors on survival. We have studied survival according to hormonal and reproductive history in a population-based cohort of 676 Australian women aged 18-79, newly diagnosed with invasive epithelial ovarian cancer in the early 1990s. In order to place our findings in context, we have also undertaken a systematic review of the pertinent literature. Detailed information about each woman's reproductive and contraceptive history was obtained from pregnancy and contraceptive calendars at the time of diagnosis. Cox regression was used to obtain multivariate adjusted hazard ratios (HR) and 95% confidence intervals (CI). A total of 419 (62%) of the 676 women died during the follow-up (giving a 5-year survival proportion of 44%). Apart from better survival for women who had ever breastfed (multivariate HR 0.74, 95% CI 0.55-0.98), we found no association between survival from invasive ovarian cancer and a range of hormonal and gynecological factors including parity, use of oral contraceptives, and histories of tubal sterilization or hysterectomy. Systematic review of the literature generally supported the lack of influence of these factors on survival from ovarian cancer. We conclude that, except for a possible survival advantage among women with a history of breastfeeding, reproductive and hormonal exposures prior to diagnosis do not influence survival from invasive ovarian cancer, in contrast to their substantial effects on etiology of this disease.

Citing Articles

Use of menopausal hormone therapy before and after diagnosis and ovarian cancer survival-A prospective cohort study in Australia.

Na R, Jordan S, DeFazio A, Williams M, Livingstone K, Obermair A Int J Cancer. 2024; 156(2):280-292.

PMID: 39222307 PMC: 11578076. DOI: 10.1002/ijc.35154.


Lifetime ovulatory years and ovarian cancer gene expression profiles.

Sasamoto N, Stewart P, Wang T, Yoder S, Chellappan S, Hecht J J Ovarian Res. 2022; 15(1):59.

PMID: 35562768 PMC: 9102743. DOI: 10.1186/s13048-022-00995-1.


What is new about ovarian malignancies?.

Grabska K, Pilarska I, Fudalej M, Deptala A, Badowska-Kozakiewicz A Contemp Oncol (Pozn). 2022; 25(4):225-231.

PMID: 35079229 PMC: 8768052. DOI: 10.5114/wo.2021.112037.


High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival.

Brieger K, Phung M, Mukherjee B, Bakulski K, Anton-Culver H, Bandera E Cancer Epidemiol Biomarkers Prev. 2021; 31(2):443-452.

PMID: 34789471 PMC: 9281656. DOI: 10.1158/1055-9965.EPI-21-0977.


Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study.

Schrijver L, Antoniou A, Olsson H, Mooij T, Roos-Blom M, Azarang L Am J Obstet Gynecol. 2021; 225(1):51.e1-51.e17.

PMID: 33493488 PMC: 8278569. DOI: 10.1016/j.ajog.2021.01.014.